MDSAP, EU MDR and Health Canada: How One Device Is Regulated Under Three Regimes

Three self-contained biological indicator vials with printed lot labels

A single sterilization-monitoring product can be audited once under MDSAP, CE marked in the European Union, and licensed in Canada — and each of those three regimes asks a different question about the same device. MDSAP audits the manufacturer's quality management system against ISO 13485 and the requirements of participating regulators; the EU Medical Device Regulation (EU) 2017/745 classifies the product and requires a conformity assessment with a notified body; Health Canada classifies the device under the Medical Devices Regulations (SOR/98-282) and issues device and establishment licences. Read the three columns below before you assume a certificate from one regime carries any weight in another — it does not.

Take a concrete example. A self-contained biological indicator, such as a CliniEco 24-hour self-contained biological indicator — 50-pack, is a Class II device under 21 CFR 880.2800(a) in the United States, is classified by rule under Canada's Schedule 1, and is assessed against a rule in Annex VIII of the MDR in the EU. The manufacturer's quality system is audited once a year under one programme instead of three separate inspections.

At a glance: one device, three regulators

Regime Governing instrument What it assesses Who evaluates Document issued Term
MDSAP MDSAP Audit Approach (MDSAP AU P0002) The manufacturer's quality management system, against ISO 13485:2016 plus the requirements of each participating regulator An MDSAP-recognized Auditing Organization MDSAP audit report / certificate Three-year cycle: initial audit, two surveillance audits, then recertification
EU Regulation (EU) 2017/745 (MDR), Articles 51–52 and Annexes VIII–XI Product classification and conformity assessment, including the technical documentation A notified body for class IIa, IIb and III (and for class I devices placed on the market sterile, with a measuring function, or as reusable surgical instruments) EU declaration of conformity plus CE marking, supported by the notified body certificate Notified body certificates are valid for the period they state, not exceeding five years
Canada Medical Devices Regulations (SOR/98-282), sections 6 and 7 with Schedule 1 Device classification and the licence application content, including the quality management system documentation Health Canada Medical device licence for class II, III and IV; establishment licence for importers and distributors Licence-based rather than a fixed term

Two points in that table are worth isolating. First, MDSAP is a QMS audit programme, not a marketing authorisation. Second, only one of the three columns ends with a document that authorises a product to be sold.

Three self-contained biological indicator vials with printed lot labels, the product type used to illustrate how one device is classified in three regimes
Biological indicators carry a printed lot label and a stated sterilization method — the same device has to be classified under Canada's Schedule 1, an Annex VIII rule in the EU, and a section of 21 CFR 880.

Which devices fall under which regime?

Regime Classification ladder Who must hold what
Canada Class I to Class IV, assigned by the classification rules in Schedule 1; Class I is the lower risk end and Class IV the higher risk end (SOR/98-282, section 6). If a device fits more than one class, the higher risk class applies (section 7) A manufacturer applying for a class II, III or IV medical device licence files a quality management system certificate, in addition to device information (section 32). Importing or selling a device requires an establishment licence, with exemptions for retailers, health care facilities and — for class II, III and IV — the manufacturer (section 44)
European Union Class I, IIa, IIb and III, assigned by the classification rules in Annex VIII; the manufacturer's intended purpose and inherent risk drive the outcome, and disputes with a notified body go to a competent authority (Article 51) Class I manufacturers self-declare conformity after drawing up the technical documentation; sterile, measuring-function and reusable surgical instruments involve a notified body for those aspects only. Class IIa, IIb and III devices follow the procedures in Annexes IX to XI (Article 52)
MDSAP No product classes — the programme audits the manufacturer's processes, not the product Any manufacturer whose device licence in Canada, or market authorisation in another participating jurisdiction, depends on a quality system audit

Does an MDSAP audit replace a product approval?

No. MDSAP lets one recognized Auditing Organization conduct a single regulatory audit of a manufacturer that satisfies the relevant requirements of the participating authorities, and the participating members are the Therapeutic Goods Administration of Australia, Brazil's ANVISA, Health Canada, Japan's MHLW and PMDA, and the U.S. Food and Drug Administration. Official observers include the European Union, Singapore's HSA, the United Kingdom's MHRA and the WHO prequalification programme for in vitro diagnostics.

The effect on the U.S. side is documented: the FDA states that it may continue to accept MDSAP audit reports as a substitute for routine Agency inspections, with the exception of activities tied to Electronic Product Radiation Control, which remain subject to inspection. That substitution concerns inspections of the quality system. It does not clear a device, and it does not change the classification or premarket pathway that applies to a product in any jurisdiction.

Health Canada's own position is that the transition to MDSAP is complete: all manufacturers holding medical device licences in Canada now participate in the programme, a transition announced in December 2015 and completed in 2019. That is why a licence application that leans on an ISO 13485 certificate is, in practice, leaning on an audit performed under the MDSAP framework.

What the MDSAP audit actually covers

An MDSAP audit is organized into seven process chapters, and each audit task names the clause or regulation it is testing:

  1. Management
  2. Device marketing authorization and facility registration
  3. Measurement, analysis and improvement
  4. Medical device adverse events and advisory notices reporting
  5. Design and development
  6. Production and service controls
  7. Purchasing

The audit approach states that the audit team reviews procedures against ISO 13485:2016 and against regulator-specific requirements — the Conformity Assessment Procedures of the Australian Therapeutic Goods (Medical Devices) Regulations, Brazilian good manufacturing practices (RDC ANVISA 665/2022), the Japanese QMS ordinance (MHLW MO 169), and the quality system regulation at 21 CFR Part 820 — together with the specific requirements of the authorities participating in the programme. Each task lists the clause and regulation references, so a manufacturer can read the expected evidence before the audit rather than after it.

One quality system, several rulebooks

Requirement source Where it appears in the MDSAP audit tasks
ISO 13485:2016 The baseline clauses cited in every chapter
Australian TG(MD)R Schedule 3, Part 1 Cited alongside the ISO clauses for management and reporting tasks
ANVISA RDC 665/2022 Cited as the Brazilian good manufacturing practice reference
MHLW Ministerial Ordinance No. 169 Cited as the Japanese QMS reference
21 CFR Part 820 Cited as the U.S. quality system reference in force when the audit approach was revised
Canadian Medical Devices Regulations Listed among the regulatory requirements addressed in the audit tasks

Note the last-but-one row carefully. The MDSAP audit approach revision in use cites 21 CFR Part 820 by its established section numbers, because that is how the U.S. quality system was written at the time. Part 820 itself has since been restructured into the quality management system regulation, which requires a manufacturer to document a quality management system complying with the applicable requirements of ISO 13485 and other applicable requirements of the part. The practical effect is that the U.S. and Canadian quality system expectations now rest on the same standard family, which is precisely the alignment MDSAP was built to exploit.

A pair of blue nitrile examination gloves on a white background, an example of a class I device with a limited premarket notification exemption
Gloves show how narrow an exemption can be: under 21 CFR 880.6250 the patient examination glove is class I, but the exemption from premarket notification applies to finger cots.

How long does each approval last?

Approval Term What restarts the clock
MDSAP audit cycle Three years: an initial audit with a Stage 1 and Stage 2 component, a partial surveillance audit in each of the following two years, and a complete recertification audit in the third year Extraordinary audits — special audits, audits conducted by regulatory authorities, and unannounced audits — can occur at any time within the cycle
Notified body certificate under the MDR The period stated on the certificate, which may not exceed five years; the manufacturer may apply to extend it for further periods, each not exceeding five years, following a re-assessment A new or changed device may require a new assessment; certificates issued under the earlier directives remained valid under the transition arrangements only until the dates set by Regulation (EU) 2023/607 (31 December 2027 for class III and implantable class IIb devices; 31 December 2028 for other class IIb, class IIa, and class I devices placed on the market sterile or with a measuring function)
Canadian device licence Tied to the device and to the quality management system certificate on file, rather than to a certificate term Changes to the device, the manufacturing establishment, or the quality system certificate keep the licence application current

The MDR has applied since 26 May 2021, a date postponed from 2020 by Regulation (EU) 2020/561, and Regulation (EU) 2023/607 amended the transitional provisions. Anyone planning a European launch should read the transition dates as deadlines that assume the device continues to comply with the earlier directives and that no significant change has been made — conditions set out in the amending regulation.

Where the three regimes still diverge

  • Class counts differ. Canada uses four classes, the EU uses four classes with a different structure, and the U.S. uses three. A class II device in Canada is not automatically a class IIa device in Europe.
  • The assessing party differs. Canada's regulator evaluates licence applications; the EU delegates conformity assessment to notified bodies for most higher-risk devices; MDSAP delegates the audit to recognized Auditing Organizations.
  • MDSAP membership and observer status differ. The European Union participates as an official observer, not as a member, so a CE mark is not evidence of an MDSAP audit.
  • The evidence bundle differs. A notified body assesses technical documentation; a licence application in Canada submits a quality management system certificate and device documentation; an MDSAP audit examines processes and records, and issues a report.

What a Canadian supplier should be able to produce on request

  • The MDSAP audit report or certificate for the manufacturing site, with the certificate's scope matching the device you are buying.
  • The quality management system standard reference in the certificate, so it can be matched against the standard named in the licence or the notified body certificate.
  • The classification rationale for the device in each market you sell into, written against the rule that applies there rather than against the class name.
  • The notified body certificate number and expiry where the product is CE marked, and the device licence number for the Canadian market.
  • The establishment licence held by the importer or distributor in the chain, since holding a licence and holding a device licence are separate things.

Sources

Written for infection control leads, clinic owners and procurement teams comparing the three routes: the MDSAP audit, the MDR for European market access, and the Canadian device licence system.

Related reading

Frequently Asked Questions

Does an MDSAP certificate let me sell a device in Canada?

No. An MDSAP audit covers the manufacturer's quality management system. Selling in Canada still requires the licence that applies to that device class — a medical device licence for class II, III and IV devices, and an establishment licence for the party importing or selling.

Is an MDSAP audit the same as an FDA inspection?

Not identical. The FDA states that it may accept MDSAP audit reports as a substitute for routine Agency inspections, except for activities tied to Electronic Product Radiation Control. The audit still examines the quality system rather than clearing a specific product.

How long is an MDSAP audit cycle?

Three years. The MDSAP audit approach describes an initial audit with Stage 1 and Stage 2 components, a partial surveillance audit in each of the next two years, and a complete recertification audit in the third year.

How long can a notified body certificate remain valid under the MDR?

The certificate is valid for the period it states, and that period may not exceed five years. A manufacturer can apply to extend it for further periods of no more than five years each, based on a re-assessment.

Is a class II device in Canada the same as a class IIa device in the EU?

No. The two systems assign classes by their own rules. Canada uses Schedule 1 of the Medical Devices Regulations; the EU uses Annex VIII of the MDR. A device has to be classified separately against the rules of each regime.

Does the European Union participate in MDSAP as a member?

The European Union participates as an official observer, alongside Singapore's HSA, the United Kingdom's MHRA and the WHO prequalification programme for in vitro diagnostics. The participating members are Australia's TGA, Brazil's ANVISA, Health Canada, Japan's MHLW and PMDA, and the U.S. FDA.

Sterilization monitoring supply for Canadian clinics — MDEL #35334. CliniEco Medical supplies biological indicators, Class 5 steam chemical integrators — 100-pack and self-seal sterilization pouches — 200-pack, assorted sizes to dental, long-term care, veterinary and laboratory settings across Canada.

Compliance and supply support

Downloadable records: the sterilization log sheet generator and record downloads cover autoclave logs, spore test results and traceability fields for audit preparation. The same log and record centre holds the printable templates used by dental, laboratory and long-term care teams.

Institutional purchasing: see wholesale and institutional supply for account setup and volume ordering, or book a sterilization compliance consultation to review documentation, monitoring records and supplier evidence before an inspection. Buyers who need to compare monitoring formats can start from the sterilization compliance hub. Reselling? become a distributor.

Already working with clinics? Become a regional representative.